Our Transactions
Transformative transactions and engagements
Locust Walk has a robust record of success in closing high-value transactions for multiple clients. Our work spans the spectrum of therapeutic areas and modalities, from cutting edge gene therapies in oncology to commercial stage specialty pharmaceutical products. A selection of our engagements appears below. Please click on each case study or news release for greater detail about each transformative transaction. Contact us if you would like to learn more.
CLIENT: Undisclosed
TRANSACTION:Financing process for Phase 2 Immuno-Oncology Company
$45M Private Financing
CLIENT: Calliditas Therapeutics
TRANSACTION: Japanese regional transaction with Viatris for specialty therapy for IgA nephropathy $20M upfront, $80M milestone plus royalties
CLIENT: Undisclosed
TRANSACTION: NewCo Formation for Transcription Factor Network Pharmacology Platform
CLIENT: Eagle Pharmaceuticals
TRANSACTION: Transaction and Corporate Development Advisor
$25M Equity Investment with Option to Acquire
CLIENT: Undisclosed
TRANSACTION: NewCo Formation for Thymic Regeneration and Immune Senescence Platforms
CLIENT: Eagle Pharmaceuticals
TRANSACTION: Commercial Due Diligence and Advisor for Acquisition
$104M Acquisition
CLIENT: Elypta
TRANSACTION: Financing process for novel cancer detection technology led to $21M Series A
CLIENT: Nanolive
TRANSACTION: Financing process for novel imaging technology achieves $20M Series C1
CLIENT: TherapeuticsMD
TRANSACTION: Dual-Track Engagement leading to $150M Acquisition with an additional $7M contingent consideration of TherapeuticsMD’s vitaCare Prescription Services business by GoodRx (NASDAQ: GDRX)
CLIENT: Garuda Therapeutics
TRANSACTION: Integrated business plan and strategy development with financing process to an oversubscribed $72M Series A
CLIENT: eFFECTOR Therapeutics
TRANSACTION: M&A advisor and PIPE placement agent for $340M acquisition and $60M PIPE
CLIENT: Gritstone
PARTNER: Gilead
TRANSACTION: Sell-side engagement for Gritstone leading to a partnership with Gilead for $60M upfront and $725M in additional payments plus tiered royalties
CLIENT: Mana Therapeutics
TRANSACTION: Robust Dual-track Process to a Successful $35M Series A Financing
CLIENT: Regenacy
PARTNER: 3E Bioventures Capital
TRANSACTION: Chinese joint venture to facilitate indication expansion opportunity
CLIENT: TWiB
TRANSACTION: Japan collaboration for a phase 2 orphan dermatology asset
CLIENT: Nevakar
TRANSACTION: Licensing agreement for NVK-002 with Zhaoke Ophthalmology in Greater China, South Korea and the Southeast Asian territories
CLIENT: C4 Therapeutics
TRANSACTION: IPO Advisory assignment helping raise $210M in a NASDAQ IPO
CLIENT: C4 Therapeutics
TRANSACTION: Rapid financing process led to oversubscribed crossover financing
CLIENT: Inspirion Delivery Sciences
TRANSACTION: Asset sale as part of court-ordered dissolution process
CLIENT: Esteve
PARTNER: Leitat
TRANSACTION: Esteve and Leitat announce strategic partnership to collaborate in research and development
CLIENT: BioPharmX
PARTNER: Timber Pharmaceuticals
TRANSACTION: Sell-side engagement leading to a reverse merger
CLIENT: Targovax
PARTNER: IOVaxis Therapeutics
TRANSACTION: Sell-side engagement leading to option agreement for greater Chinese rights
CLIENT: Xyphos
PARTNER: Astellas
TRANSACTION: Multi-Track Engagement Leading to Acquisition of Xyphos by Astellas
CLIENT: Chimerix
PARTNER: SymBio Pharmaceuticals Limited
TRANSACTION: Exclusive global licensing agreement with SymBio Pharmaceuticals for Brincidofovir
CLIENT: Pipeline Therapeutics
PARTNER: Sirocco Therapeutics
TRANSACTION: Rapid M&A advisory
CLIENT: Mesa Biotech
TRANSACTION:
Growth capital for point-of-care diagnostic product company
$20M Private Placement
CLIENT: Rapid Micro Biosystems
TRANSACTION:
Growth capital for automated, rapid microbial detection system for the healthcare product manufacturing sector
CLIENT: Pernix Therapeutics
PARTNER: Orexigen Therapeutics
TRANSACTION: Advisor to Pernix in its acquisition of Orexigen Therapeutics for $73.5M
CLIENT: Flora Bioscience
PARTNER: Olm Diagnostics
TRANSACTION: Led sell-side partnering process for a women’s health infectious disease POC diagnostic
CLIENT: HCRP
PARTNER: Albireo
TRANSACTION: Advised on commercial potential of elobixibat in Japan
CLIENT: Corsair Pharma
PARTNER: United Therapeutics
TRANSACTION: Exclusive IP licensing agreement
CLIENT: Histogenics
PARTNER: MEDINET
TRANSACTION: Sell-Side process for NeoCart® leading to a Japan licensing agreement with MEDINET
CLIENT: Regeneron
PARTNER: Asahi Kasei Pharma
TRANSACTION: Facilitated negotiations between the US and Japan leading to the partnering in Japan of Sarilumab
CLIENT: TesoRx
PARTNER: ASKA
TRANSACTION: Advised on expansion of existing collaboration on TSX-011 in addition to ASKA equity investment in TesoRx
CLIENT: Spero Therapeutics
PARTNER: Meiji Seika Pharma Co.,Ltd
TRANSACTION: Advised on Japan buy-side process leading to exclusive License Agreement for Meiji’s carbapenem, SPR-994
CLIENT: Veloce BioPharma
PARTNER: Maruho
TRANSACTION: Assisted partnership with Maruho including an equity investment from Maruho into Veloce
PARTNER: Gurnet Point Capital
TRANSACTION: Advised on company acquisition
CLIENT: Pieris
PARTNER: Servier
TRANSACTION:
Global Multi-Program Immuno-Oncology Alliance
CLIENT: Pieris
PARTNER: ASKA Pharmaceutical
TRANSACTION:
Sell-side Japan/Asia collaboration PRS-080
CLIENT: TesoRX
PARTNER: ASKA Pharmaceutical
TRANSACTION:
Sell-side Japan licensing agreement for THG-1001
CLIENT: CymaBay Therapeutics
PARTNER: Kowa
TRANSACTION:
Sell-Side Process Leading to US licensing agreement for arhalofenate
CLIENT: Strongbridge Biopharma
PARTNER: TaroPharma
TRANSACTION:
Buy-side US rights acquisition for Keveyis
CLIENT: Thar Pharmaceuticals
TRANSACTION:
Multi-Track Sell-Side and Financing Engagement Leading to Acquisition
CLIENT: NeoTX Therapeutics
PARTNER: Active Biotech
TRANSACTION:
Buy-side licensing agreement for ANYARA
CLIENT: Savara
PARTNER: Serendex Pharmaceutical
TRANSACTION:
Identified and Initiated buy-side acquisition
CLIENT: Strategic Science & Technologies, LLC
TRANSACTION:
Sell-side license for Canadian rights of IbuCream
CLIENT: Advaxis Immunotherapies
TRANSACTION:
Immuno- Oncology Advisor
CLIENT: Medgenics, Inc.
PARTNER: Kyowa Hakko Kirin
TRANSACTION:
Leveraging relationships in Japan to facilitate collaboration to develop and commercialize KHK’s anti-LIGHT mAb.
CLIENT: Strongbridge Biopharma
TRANSACTION:
Raised $25M in a U.S. initial public offering issuing 2,500,000 shares at $10 per share
CLIENT: Regeneron
PARTNER: Mitsubishi Tanabe Pharma
TRANSACTION:
Facilitating negotiations between US and Japan to speed deal execution.
CLIENT: Armetheon
PARTNER: Lees Pharma
TRANSACTION:
Agreement to Develop and Commercialize Tecarfarin in Greater China and Thailand
CLIENT: Strongbridge Biopharma
PARTNER: Antisense Therapeutics
TRANSACTION:
Buy-side licensing agreement for ALT1103 for Acromegaly
CLIENT: Strongbridge
Biopharma
PARTNER: Investors
TRANSACTION:
Private Placement of $26.4M
CLIENT: Strategic Science & Technologies, LLC
PARTNER: Global OTC Player
TRANSACTION:
US Option Agreement for IbuCream (topical ibuprofen)
CLIENT: Onxeo
PARTNER: Dara BioSciences
TRANSACTION:
Commercialization agreement for North American rights to Oravig
CLIENT: Strongbridge Biopharma
PARTNER: Aspireo Pharmaceuticals
TRANSACTION:
Buy-side product acquisition of Somatoprim for Acromegaly
CLIENT: Strongbridge Biopharma
PARTNER: Investors
TRANSACTION:
Private Placement of $33.2M
CLIENT: TesoRx
PARTNER: Aspen
TRANSACTION:
Regional License Agreement and Investment for an Oral Unmodified Testosterone Replacement.
CLIENT: Fabrus
PARTNER: Senesco
TRANSACTION:
Merger between Fabrus and Senesco Technologies
CLIENT: BioAlliance Pharma
PARTNER: Innocutis
TRANSACTION:
US Commercialization Agreement for Sitavig® (acyclovir mucoadhesive tablet)
CLIENT: Otsuka
PARTNER: Proteus
TRANSACTION:
Worldwide License and Collaboration Agreement
CLIENT: InterMune
PARTNER: Vidara
TRANSACTION:
Actimmune Product Divestiture for $55M upfront plus 2 year royalty
CLIENT: Otsuka
PARTNER: Lundbeck
TRANSACTION:
Worldwide Co-Pro, Co-Dev Agreement for Abilify Depotand OPC-34712
CLIENT: Ascenta
PARTNER: Debiopharm Group
TRANSACTION:
Worldwide Licensing Agreement for AT-406
CLIENT: Angiochem
PARTNER: Geron
TRANSACTION:
Worldwide Licensing Agreement for ANG1005 and Research Collaboration for Telomerase
CLIENT: Synthetic Genomics
PARTNER: Novartis
TRANSACTION:
Advisor in Forming New Company Synthetic Genomics Vaccines Inc. and Advisor on Structuring
CLIENT: Strategic Science & Technologies, LLC
PARTNER: Undisclosed
TRANSACTION:
Worldwide Licensing Agreement for IbuCream (topical ibuprofen)
CLIENT: Concordia Pharmaceuticals
PARTNER: Ono
TRANSACTION:
Licensing Agreement for Salirasib in Japan